Table 1. Patient Characteristics at Baseline.
| Characteristic | Combined Phases 1 and 2 Patients With Ovarian Carcinoma (n = 62) |
|---|---|
| Age, median (range), y | 60 (46-83) |
| ECOG performance status, No. (%)a | |
| 0 | 44 (71) |
| 1 | 18 (29) |
| Prior lines of therapy, median (range) | 3 (1-5) |
| Prior bevacizumab, No. (%) | 39 (63) |
| Prior chemotherapy, No. (%)b | |
| Anthracycline | 40 (65) |
| Cyclophosphamide | 5 (8) |
| Gemcitabine hydrochloride | 29 (47) |
| Paclitaxel | 61 (98) |
| Platinum | 62 (100) |
| Topotecan hydrochloride | 3 (5) |
| Platinum status, No. (%) | |
| Resistant | 30 (48) |
| Refractory | 17 (27) |
| Not applicablec | 15 (24) |
| tBRCA status, No. (%) | |
| BRCA1 mutation | 9 (15) |
| BRCA2 mutation | 2 (3) |
| BRCA wild type | 49 (79) |
| Unknown | 2 (3) |
| HRD status, No. (%) | |
| HRD positive | 22 (35) |
| HRD negative | 33 (53) |
| HRD unknown | 7 (11) |
| PD-L1 status, No. (%)d | |
| Positive | 35 (56) |
| Negative | 21 (34) |
| Unknown | 6 (10) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; HRD, homologous recombination deficiency; PD-L1, programmed death-ligand 1; tBRCA, tumor BRCA.
a
Zero indicates fully active and able to perform all predisease activities without restriction; 1, restricted in strenuous activity yet ambulatory and able to do light work.
b
Includes chemotherapy used in more than 1 patient; those used in only 1 patient are not listed.
c
Includes patients with an interval free of platinum-based chemotherapy of at least 180 days but unable to receive further platinum-based chemotherapy (owing to toxic effect or allergic reaction).
d
Positivity was based on a combined positive score of 1 provisional cutoff by immunohistochemistry.